We established NPC organoids from an EBV+ NPC patient-derived xenograft (Xeno76) established in 201847, and evaluated CD70 and PD-L1 expression levels in Xeno76 accordingly (Fig. 4j). This evidence concerns the gene CD70 and nasopharyngeal carcinoma.